Published in Blood on December 01, 2001
Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood (2007) 2.09
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood (2014) 1.62
Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens. Exp Hematol (2008) 1.48
Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis. PLoS One (2012) 1.20
In vitro megakaryocyte differentiation and proplatelet formation in Ph-negative classical myeloproliferative neoplasms: distinct patterns in the different clinical phenotypes. PLoS One (2011) 1.15
Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. J Clin Invest (2012) 1.09
Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis. Am J Pathol (2005) 1.05
Gene and microRNA analysis of neutrophils from patients with polycythemia vera and essential thrombocytosis: down-regulation of micro RNA-1 and -133a. J Transl Med (2009) 1.00
Enhanced expression of Stim, Orai, and TRPC transcripts and proteins in endothelial progenitor cells isolated from patients with primary myelofibrosis. PLoS One (2014) 0.93
Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agents. Cancer Res (2009) 0.92
Inflammation as a Keystone of Bone Marrow Stroma Alterations in Primary Myelofibrosis. Mediators Inflamm (2015) 0.90
Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. Biol Blood Marrow Transplant (2010) 0.87
High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk of splanchnic vein thrombosis. PLoS One (2010) 0.85
Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation. Leuk Lymphoma (2013) 0.85
Transcriptional profiling of whole blood identifies a unique 5-gene signature for myelofibrosis and imminent myelofibrosis transformation. PLoS One (2014) 0.85
A Pilot Study of Quantitative MRI Parametric Response Mapping of Bone Marrow Fat for Treatment Assessment in Myelofibrosis. Tomography (2016) 0.85
Transcription factor nuclear factor erythroid-2 mediates expression of the cytokine interleukin 8, a known predictor of inferior outcome in patients with myeloproliferative neoplasms. Haematologica (2013) 0.84
Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives. J Cell Mol Med (2009) 0.83
Functional evaluation of circulating hematopoietic progenitors in Noonan syndrome. Oncol Rep (2013) 0.79
C-X-C motif chemokine 12 influences the development of extramedullary hematopoiesis in the spleens of myelofibrosis patients. Exp Hematol (2014) 0.79
CD133 marks a stem cell population that drives human primary myelofibrosis. Haematologica (2015) 0.78
Myeloproliferative Neoplasms in Children. J Hematop (2015) 0.78
Crucial factors of the inflammatory microenvironment (IL-1β/TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study. Oncotarget (2016) 0.76
Pulmonary extra-medullary hematopoiesis and pulmonary hypertension from underlying polycythemia vera: a case series. Pulm Circ (2017) 0.76
A 7-Gene Signature Depicts the Biochemical Profile of Early Prefibrotic Myelofibrosis. PLoS One (2016) 0.75
Tie2 Expressing Monocytes in the Spleen of Patients with Primary Myelofibrosis. PLoS One (2016) 0.75
Factors affecting prognosis in myelofibrosis. F1000 Med Rep (2009) 0.75
MPL W515L expression induces TGFβ secretion and leads to an increase in chemokinesis via phosphorylation of THOC5. Oncotarget (2016) 0.75
Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood (2016) 0.75
Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis. J Exp Med (2016) 0.75
CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner. Oncotarget (2016) 0.75
Diagnostic and prognostic value of colony formation of hematopoietic progenitor cells in myeloid malignancies. Wien Klin Wochenschr (2003) 0.75
WHO antenatal care randomised trial for the evaluation of a new model of routine antenatal care. Lancet (2001) 6.86
WHO multicentre randomised trial of misoprostol in the management of the third stage of labour. Lancet (2001) 5.25
WHO systematic review of randomised controlled trials of routine antenatal care. Lancet (2001) 3.93
Timing of emergency contraception with levonorgestrel or the Yuzpe regimen. Task Force on Postovulatory Methods of Fertility Regulation. Lancet (1999) 2.99
Interventions for emergency contraception. Cochrane Database Syst Rev (2008) 2.04
Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplant (2009) 2.03
Role of the Helicobacter pylori virulence factors vacuolating cytotoxin, CagA, and urease in a mouse model of disease. Infect Immun (1995) 1.93
Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant (2005) 1.79
Interventions for emergency contraception. Cochrane Database Syst Rev (2004) 1.75
Chronic musculoskeletal pain and depressive symptoms in the National Health and Nutrition Examination. I. Epidemiologic follow-up study. Pain (1993) 1.72
Familial-skewed X-chromosome inactivation as a predisposing factor for late-onset X-linked sideroblastic anemia in carrier females. Blood (2000) 1.71
Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria. Haematologica (2000) 1.66
NF-Y mediates the transcriptional inhibition of the cyclin B1, cyclin B2, and cdc25C promoters upon induced G2 arrest. J Biol Chem (2000) 1.64
Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells. Mol Cell Biol (2000) 1.60
Misoprostol dose and route after mifepristone for early medical abortion: a randomised controlled noninferiority trial. BJOG (2010) 1.57
Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection. Infect Immun (1997) 1.57
Quality of life in 244 recipients of allogeneic bone marrow transplantation. Br J Haematol (2000) 1.55
Intravenous iron therapy for severe anaemia in systemic-onset juvenile chronic arthritis. Lancet (1994) 1.52
Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial. Blood (1992) 1.49
New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia. Haematologica (1997) 1.47
The cyclin B2 promoter depends on NF-Y, a trimer whose CCAAT-binding activity is cell-cycle regulated. Oncogene (1999) 1.47
Increased sensitivity to complement and a decreased red blood cell life span in mice mosaic for a nonfunctional Piga gene. Blood (1999) 1.46
Coagulation and cancer: biological and clinical aspects. J Thromb Haemost (2013) 1.42
Patterns of routine antenatal care for low-risk pregnancy. Cochrane Database Syst Rev (2001) 1.41
Mobilization and transplantation of Philadelphia-negative peripheral-blood progenitor cells early in chronic myelogenous leukemia. J Clin Oncol (1997) 1.41
Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leuk Res (2010) 1.40
Walking index for spinal cord injury (WISCI): an international multicenter validity and reliability study. Spinal Cord (2000) 1.40
Splenic irradiation before bone marrow transplantation for chronic myeloid leukaemia. Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) Br J Haematol (1996) 1.40
Distinctive integrin expression in the newly forming epidermis during wound healing in humans. J Invest Dermatol (1993) 1.39
Adhesive receptors, extracellular proteins and myosin IIA orchestrate proplatelet formation by human megakaryocytes. J Thromb Haemost (2008) 1.39
Pre-emptive therapy of acute graft-versus-host disease: a pilot study with antithymocyte globulin (ATG). Bone Marrow Transplant (2001) 1.39
The myelodysplastic syndromes: predictive value of eight prognostic systems in 143 cases from a single institution. Haematologica (1999) 1.38
Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood (1991) 1.36
Down-regulation of cyclin B1 gene transcription in terminally differentiated skeletal muscle cells is associated with loss of functional CCAAT-binding NF-Y complex. Oncogene (1999) 1.35
Cluster randomised trial of an active, multifaceted educational intervention based on the WHO Reproductive Health Library to improve obstetric practices. BJOG (2006) 1.35
Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood (2000) 1.34
Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo. Bone Marrow Transplant (2011) 1.32
The transcriptional repressor ZEB regulates p73 expression at the crossroad between proliferation and differentiation. Mol Cell Biol (2001) 1.29
p53 regulates myogenesis by triggering the differentiation activity of pRb. J Cell Biol (2000) 1.25
Factors affecting the comparability of meta-analyses and largest trials results in perinatology. J Clin Epidemiol (1997) 1.24
The ultrastructural localization of factor VIII-antigen in human platelets, megakaryocytes and endothelial cells utilizing a ferritin-labelled antibody. Br J Haematol (1978) 1.21
Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol (2001) 1.21
Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation. Bone Marrow Transplant (2007) 1.21
Kinetic studies on rifampicin. I. Serum concentration analysis in subjects treated with different oral doses over a period of two weeks. Chemotherapy (1971) 1.20
Platelet size distinguishes between inherited macrothrombocytopenias and immune thrombocytopenia. J Thromb Haemost (2009) 1.20
Unbalanced X-chromosome inactivation in haemopoietic cells from normal women. Br J Haematol (1998) 1.20
Transformation-dependent susceptibility of rat hepatic stellate cells to apoptosis induced by soluble Fas ligand. Hepatology (1998) 1.19
Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor. Blood (1999) 1.17
The efficiency of walking of paraplegic patients using a reciprocating gait orthosis. Paraplegia (1995) 1.16
Store-dependent Ca(2+) entry in endothelial progenitor cells as a perspective tool to enhance cell-based therapy and adverse tumour vascularization. Curr Med Chem (2012) 1.16
Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. J Clin Oncol (2002) 1.15
Gene structure, localization and role in oxidative stress of methionine sulfoxide reductase A (MSRA) in the monkey retina. Exp Eye Res (2005) 1.15
Cost of walking and locomotor impairment. J Electromyogr Kinesiol (1999) 1.15
Cytogenetic follow-up after bone marrow transplantation for Philadelphia-positive chronic myeloid leukemia. Cancer Genet Cytogenet (1989) 1.14
Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose. Br J Haematol (2001) 1.14
X inactivation and somatic cell selection rescue female mice carrying a Piga-null mutation. Proc Natl Acad Sci U S A (1999) 1.12
Selective effect of feline leukaemia virus on early erythroid precursors. Nature (1982) 1.12
Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age. Br J Haematol (2000) 1.09
Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol (2001) 1.08
Statistical methods for the meta-analysis of cluster randomization trials. Stat Methods Med Res (2001) 1.08
The epidemiology of syphilis in pregnancy. Int J STD AIDS (2002) 1.08
Mitochondrial complex I defects in aging. Mol Cell Biochem (1997) 1.08
The cyclin B1 gene is actively transcribed during mitosis in HeLa cells. EMBO Rep (2001) 1.06
The retroviral transduction of HOXC4 into human CD34(+) cells induces an in vitro expansion of clonogenic and early progenitors. Exp Hematol (2000) 1.06
A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes. Oncogene (2009) 1.05
Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. The WHO Study of Hormonal Contraception and Bone Health. Obstet Gynecol (2000) 1.05
Wild-type p53 gene expression induces granulocytic differentiation of HL-60 cells. Blood (1994) 1.05
Deciding when to intervene: a Markov decision process approach. Int J Med Inform (2000) 1.04
Molecular imaging of inflammation/infection: nuclear medicine and optical imaging agents and methods. Chem Rev (2010) 1.04
Natural distribution and occurrence of coenzyme Q homologues. Membr Biochem (1992) 1.02
Cloning and expression of human NF-YC. Gene (1997) 1.02
Which is the most suitable and effective route of administration for mesenchymal stem cell-based immunomodulation therapy in experimental kidney transplantation: endovenous or arterial? Transplant Proc (2010) 1.02
Vesicoureteral reflux and ureteropelvic junction obstruction in children with horseshoe kidney: treatment and outcome. J Urol (2002) 1.01
The interplay of muscular and external forces in human ambulation. J Biomech (1976) 1.00
No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol (2000) 0.99
Unbiased next generation sequencing analysis confirms the existence of autosomal dominant Alport syndrome in a relevant fraction of cases. Clin Genet (2013) 0.98
Inherited thrombocytopenias: the evolving spectrum. Hamostaseologie (2012) 0.97
Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukemia (2003) 0.97
Proplatelet formation in heterozygous Bernard-Soulier syndrome type Bolzano. J Thromb Haemost (2008) 0.96
[Biological role of folic acid]. Acta Vitaminol Enzymol (1971) 0.96
Vitamin B6 deficiency affects antioxidant defences in rat liver and heart. Biochem Mol Biol Int (1998) 0.95
The WHO antenatal care randomised controlled trial: rationale and study design. Paediatr Perinat Epidemiol (1998) 0.95
Detoxification of the Helicobacter pylori cytotoxin. Infect Immun (1997) 0.95
Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia? Br J Haematol (2000) 0.95
Allogeneic bone marrow transplantation (BMT) for refractory Behçet's disease with severe CNS involvement. Bone Marrow Transplant (2006) 0.95
The impact of center experience on results of reduced intensity: allogeneic hematopoietic SCT for AML. An analysis from the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant (2012) 0.94
Apoptosis: biological and clinical aspects. Haematologica (2004) 0.94
Conventional hematopoietic stem cell transplants from identical or alternative donors are feasible in recipients relapsing after an autograft. Haematologica (2001) 0.94
Mesenchymal stem cells infusion prevents acute cellular rejection in rat kidney transplantation. Transplant Proc (2010) 0.94
HSP-CBF is an NF-Y-dependent coactivator of the heat shock promoters CCAAT boxes. J Biol Chem (2001) 0.93
High dose bolus methylprednisolone for the treatment of acute graft versus host disease. Blut (1983) 0.93